At one dose, 77% of patients on Johnson & Johnson's experimental drug saw a prostate cancer marker fall by 50% or more.
At one dose, 77% of patients on Johnson & Johnson's experimental drug saw a prostate cancer marker fall by 50% or more. Stock Titan
Covered in this story
Analyst targets on Johnson & Johnson
- Bernstein: $253 → $270 by Oct 2027 · Market Perform via Investing.com
- RBC Capital Markets: $249 → $280 by Oct 2027 · Outperform via GuruFocus
- RBC Capital Markets: $255 → $290 by Oct 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $JNJ yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Johnson & Johnson →Dalsna Finance is currently tracking 43 stories mentioning Johnson & Johnson, the earliest published 2 Apr 2026.
Summary aggregated from Stock Titan's public RSS feed. The full reporting belongs to Stock Titan — please read it on their site.